---
title: "Sedentary Time Modifies VO2max Response to Moderate Exercise in De Novo Parkinson Disease (SPARX P"
id: "medrxiv-0-interaction-between-exercise-intensity-and-sedentary-behavior-on-vo2max-change"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-0-interaction-between-exercise-intensity-and-sedentary-behavior-on-vo2max-change"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.30.26364437v1?rss=1"
published_at: "2026-10-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Sedentary Time Modifies VO2max Response to Moderate Exercise in De Novo Parkinson Disease (SPARX P
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-0-interaction-between-exercise-intensity-and-sedentary-behavior-on-vo2max-change
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.30.26364437v1?rss=1)
- **Published At:** 2026-10-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The SPARX Phase 2 randomized clinical trial enrolled 128 individuals with de novo Parkinson disease (PD) and compared 6 months of high-intensity treadmill exercise, moderate-intensity treadmill exercise, and usual care. - The analysis examined whether **sedentary time** over the 6-month intervention interacted with assigned **exercise intensity** to influence change in maximal oxygen consumption (**VO2max**). - Interaction models used linear regression/ANCOVA frameworks assessing 6-month change in VO2max with interaction terms between randomized group and average post-randomization sedentary time. - For the moderate-intensity group versus usual care the primary interaction was not statistically significant (β = -1.78, 95% CI -3.76 to 0.20, p = 0.08), but a complete-case sensitivity analysis found a significant interaction: each 10% greater average sedentary time was associated with a 2.51 mL/kg/min smaller VO2max change (β = -2.51, 95% CI -4.53 to -0.48, p = 0.02). - No significant interaction was observed for the high-intensity group versus usual care (β = -1.46, 95% CI -4.74 to 1.83, p = 0.38); sensitivity analyses were consistent with this null finding. - Authors report these results as preliminary and hypothesis-generating, suggesting **sedentary behavior** may attenuate benefit from **moderate-intensity** aerobic training but not necessarily from **high-intensity** training. - The paper calls for adequately powered randomized trials to confirm whether sedentary time should be considered when prescribing exercise in PD. - Trial registration: NCT01506479. Ethical approvals were obtained from the institutional review boards at participating sites; data were shared with NINDS in May 2017 and requests directed to NINDS. - Funders included NINDS and multiple institutional and foundation sources; authors declared no competing interests.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=3HjZagCdiR5Ma7qWjvMku4N8Utu3G.YYODKJcQeWUGQ-1790952884.9114642-1.2.1.1-Yuatdzm2AO9C8X.pR.ch4ClUy8rp7_x1hB1mii8Idf15ZkIRJKjZq67JhE6AAhlS) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.30.26364437v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Interaction Between Exercise Intensity and Sedentary Behavior on VO2max Change in Patients with De Novo Parkinson Disease: The Study in Parkinson Disease of Exercise (SPARX) Phase 2 Randomized Clinical Trial Byung Joon Pae, Tom S. Novak, Garett J. Griffith, Charity G. Patterson, Madeleine E. Hackney, Cory L. Christiansen, Daniel M. Corcos, Joe R. Nocera doi: https://doi.org/10.64898/2026.09.30.26364437 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Byung Joon Pae 1 Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Byung%2BJoon%2BPae%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Pae%20BJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AByung%2BJoon%2BPae%2B) Tom S. Novak 2 Center for Visual and Neurocognitive Rehabilitation (CVNR), Atlanta VAMC, Decatur, GA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tom%2BS.%2BNovak%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Novak%20TS&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATom%2BS.%2BNovak%2B) Garett J. Griffith 3 Department of Physical Therapy and Human Movement Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Garett%2BJ.%2BGriffith%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Griffith%20GJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AGarett%2BJ.%2BGriffith%2B) Charity G. Patterson 4 Department of Physical Therapy, School of Health and Rehabilitation Sciences, University of Pittsburgh, Pittsburgh, PA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Charity%2BG.%2BPatterson%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Patterson%20CG&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACharity%2BG.%2BPatterson%2B) Madeleine E. Hackney 2 Center for Visual and Neurocognitive Rehabilitation (CVNR), Atlanta VAMC, Decatur, GA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Madeleine%2BE.%2BHackney%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hackney%20ME&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMadeleine%2BE.%2BHackney%2B) Cory L. Christiansen 5 Physical Therapy Program, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Cory%2BL.%2BChristiansen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Christiansen%20CL&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACory%2BL.%2BChristiansen%2B) Daniel M. Corcos 3 Department of Physical Therapy and Human Movement Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Daniel%2BM.%2BCorcos%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Corcos%20DM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADaniel%2BM.%2BCorcos%2B) Joe R. Nocera 2 Center for Visual and Neurocognitive Rehabilitation (CVNR), Atlanta VAMC, Decatur, GA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Joe%2BR.%2BNocera%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Nocera%20JR&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJoe%2BR.%2BNocera%2B) * For correspondence: joenocera@emory.edu * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.30.26364437v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1312158/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.30.26364437v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1312158/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.30.26364437v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1312158/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.09.30.26364437v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1312158/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.30.26364437v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1312158/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.30.26364437v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1312158/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract **Background** Parkinson disease (PD) is associated with increased sedentary time and reduced cardiorespiratory fitness, making exercise an important component of disease management. Although exercise improves cardiorespiratory fitness, individuals with PD vary substantially in their response to exercise. Sedentary time may contribute to this variability, yet whether sedentary time modifies the response to intervention and varying exercise intensities within an intervention is unknown. We examined whether sedentary time interacted with 6 months of moderate-intensity or high-intensity aerobic exercise on maximal oxygen consumption (VO2max) in individuals with PD. **Methods** This secondary analysis used data from the SPARX phase 2 randomized clinical trial including 128 de novo PD patients assigned to high- or moderate-intensity treadmill exercise, or usual care for 6 months. Interactions between randomized group and post-randomization 6-months average sedentary time were assessed for associations with 6-month change in VO2max by using linear regression models corresponding to Analysis of Covariance (ANCOVA) models with interaction. **Results** The interaction between exercise intensity and sedentary behavior on 6-month change in VO2max in the moderate-intensity group compared with usual care was not significant (β: -1.78, 95% CI: -3.76 to 0.20, p-value: 0.08), although the sensitivity analysis restricted to complete cases showed a significant interaction where each 10% increase in 6-months average sedentary time was associated with a 2.51 mL/kg/min decrease in VO2max change in the moderate-intensity group compared with usual care (β: -2.51, 95% CI: -4.53 to -0.48, p-value: 0.02). There was no significant interaction between exercise intensity and sedentary behavior on 6-month change in VO2max in the high-intensity group compared with usual care (β: -1.46, 95% CI: -4.74 to 1.83, p-value: 0.38). The sensitivity analysis showed similar results. **Conclusions** These hypothesis-generating, preliminary findings suggest that sedentary time may modify the response to exercise among individuals participating in moderate-intensity aerobic exercise. Future adequately powered randomized controlled trials are needed to confirm these findings and determine whether sedentary behavior should be considered when prescribing exercise for individuals with PD. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial NCT01506479 ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee/IRB of all participating sites (University of Colorado, University of Illinois at Chicago, Northwestern University, Rush University Medical Center, University of Pittsburgh) gave ethical approval for the SPARX trial. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The original SPARX data was shared with NINDS in May, 2017, and all requests should be sent to NINDS ## Funder Information Declared National Institute of Neurologic Disease and Stroke, NINDSR01 NS074343 University of Pittsburgh Clinical and Translational Science Institute, UL1 TR000005 University of Colorado Clinical and Translational Science Award program, UL1 TR001082 Nutrition and Obesity Research Center, P30 DK048520 National Institutes of Health, K12 HD 055931 Parkinson’s Disease Foundation Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.30.26364437v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.12.26360276v2 "Multi-model LLM assessment of Quality Control Circle methodological quality: a designed-anchor reliability study")[Next ](https://www.medrxiv.org/content/10.64898/2026.09.24.26363867v1 "Exploring Ensemble Selection for Model Averaging in Model-informed Precision Dosing: A Tacrolimus Case Study Extended to Cefepime and InfliximabExploring Ensemble Selection for Model Averaging in Model-informed Precision Dosing: A Tacrolimus Case Study E…") Posted October 02, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.30.26364437v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/10/02/2026.09.30.26364437.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.30.26364437v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.09.30.26364437v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/10/02/2026.09.30.26364437.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Interaction Between Exercise Intensity and Sedentary Behavior on VO2max Change in Patients with De Novo Parkinson Disease: The Study in Parkinson Disease of Exercise (SPARX) Phase 2 Randomized Clinical Trial Byung Joon Pae, Tom S. Novak, Garett J. Griffith, Charity G. Patterson, Madeleine E. Hackney, Cory L. Christiansen, Daniel M. Corcos, Joe R. Nocera medRxiv 2026.09.30.26364437; doi: https://doi.org/10.64898/2026.09.30.26364437 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.30.26364437v1%26text%3DInteraction%2520Between%2520Exercise%2520Intensity%2520and%2520Sedentary%2520Behavior%2520on%2520VO2max%2520Change%2520in%2520Patients%2520with%2520De%2520Novo%2520Parkinson%2520Disease%253A%2520The%2520Study%2520in%2520Parkinson%2520Disease%2520of%2520Exercise%2520%2528SPARX%2529%2520Phase%25202%2520Randomized%2520Clinical%2520Trial "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.30.26364437v1%26t%3DInteraction%2520Between%2520Exercise%2520Intensity%2520and%2520Sedentary%2520Behavior%2520on%2520VO2max%2520Change%2520in%2520Patients%2520with%2520De%2520Novo%2520Parkinson%2520Disease%253A%2520The%2520Study%2520in%2520Parkinson%2520Disease%2520of%2520Exercise%2520%2528SPARX%2529%2520Phase%25202%2520Randomized%2520Clinical%2520Trial "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.30.26364437v1%26title%3DInteraction%2520Between%2520Exercise%2520Intensity%2520and%2520Sedentary%2520Behavior%2520on%2520VO2max%2520Change%2520in%2520Patients%2520with%2520De%2520Novo%2520Parkinson%2520Disease%253A%2520The%2520Study%2520in%2520Parkinson%2520Disease%2520of%2520Exercise%2520%2528SPARX%2529%2520Phase%25202%2520Randomized%2520Clinical%2520Trial%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.30.26364437v1%26title%3DInteraction%2520Between%2520Exercise%2520Intensity%2520and%2520Sedentary%2520Behavior%2520on%2520VO2max%2520Change%2520in%2520Patients%2520with%2520De%2520Novo%2520Parkinson%2520Disease%253A%2520The%2520Study%2520in%2520Parkinson%2520Disease%2520of%2520Exercise%2520%2528SPARX%2529%2520Phase%25202%2520Randomized%2520Clinical%2520Trial "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.09.30.26364437) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.09.30.26364437v1&count=horizontal&via=&text=Interaction%20Between%20Exercise%20Intensity%20and%20Sedentary%20Behavior%20on%20VO2max%20Change%20in%20Patients%20with%20De%20Novo%20Parkinson%20Disease%3A%20The%20Study%20in%20Parkinson%20Disease%20of%20Exercise%20%28SPARX%29%20Phase%202%20Randomized%20Clinical%20Trial&counturl=www.medrxiv.org/content/10.64898/2026.09.30.26364437v1 "Tweet This") ## Subject Area * [Neurology ](https://www.medrxiv.org/collection/neurology) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (623) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (910) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (339) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4872) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (483) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (420) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (658) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1640) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16044) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (34) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1215) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7116) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (735) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1072) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5107) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1445) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1788) * [Hematology](https://www.medrxiv.org/coll
## Related Clinical Research

- [Ultra-processed foods linked to MRI signs of vascular brain injury in middle-aged adults](https://medichelpline.com/clinical-feed/medical-news-today-0-ultra-processed-foods-may-be-harming-brain-health-in-otherwise-healthy-adults.md)
- [Global dementia incidence projected to reach 24.7 million new cases annually by 2050](https://medichelpline.com/clinical-feed/medical-news-today-0-dementia-cases-to-double-by-2050-why-women-some-countries-may-be-at-higher-risk.md)
- [Two scientists to receive 2026 Ralph L. Sacco Scholarships for Brain Health](https://medichelpline.com/clinical-feed/aha-news-8-two-scientists-to-receive-2026-ralph-l-sacco-scholarships-for-brain-health.md)
- [Patient-specific subnetwork connectivity predicts DBS response in OCD](https://medichelpline.com/clinical-feed/medrxiv-17-patient-specific-subnetwork-connectivity-predicts-deep-brain-stimulation.md)
- [Selectivity Dilution in Three-Factor Learning: Implications for Motor Development and Post-Stroke](https://medichelpline.com/clinical-feed/biorxiv-6-selectivity-dilution-in-three-factor-learning-a-finite-population-model-with.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.